DURHAM, N.C. (AP) _ BioCryst Pharmaceuticals Inc. (BCRX) on Wednesday reported a loss of $17.8 million in its fourth quarter.
The Durham, North Carolina-based company said it had a loss of 10 cents per share. Losses, adjusted for non-recurring gains, were 40 cents per share.
The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share.
The drugmaker posted revenue of $47.2 million in the period, also missing Street forecasts. Five analysts surveyed by Zacks expected $48.2 million.
For the year, the company reported that its loss widened to $184.1 million, or $1.03 per share. Revenue was reported as $157.2 million.
BioCryst shares have increased 28% since the beginning of the year. The stock has climbed 54% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News